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Abstract 28 
Background  Bovine colostrum (COL) has been advocated as a nutritional countermeasure 29 
to exercise-induced immune dysfunction but there is a lack of research with clinically relevant 30 
in vivo measures.  31 
Aim To investigate the effects of COL supplementation on in vivo immunity following 32 
prolonged exercise using experimental contact hypersensitivity (CHS) with the novel antigen 33 
Diphenylcyclopropenone (DPCP). 34 
Methods In a double-blind design, 31 men were randomly assigned to COL (20 g/day) 35 
or placebo (PLA) for 58 days. Participants ran for 2 h at 60% maximal aerobic capacity on 36 
day 28 and received a primary DPCP exposure (sensitisation) 20 min after. On day 56, 37 
participants received a low dose-series DPCP challenge to elicit recall of in vivo immune-38 
specific memory (quantified by skinfold thickness 24 h and 48 h later). Analysis of the dose 39 
response curves allowed determination of the minimum dose required to elicit a positive 40 
response (i.e. sensitivity). 41 
Results  There was no difference in summed skinfold thickness responses between 42 
COL and PLA at 24 h (p = 0.124) and 48 h (p = 0.405). However, sensitivity of in vivo immune 43 
responsiveness was greater with COL at 24 h (p < 0.001) and 48 h (p = 0.023) with doses ~2-44 
fold greater required to elicit a positive response in PLA.  45 
Conclusions COL blunts the prolonged exercise-induced decrease in clinically relevant in 46 
vivo immune responsiveness to a novel antigen, which may be a mechanism for reduced 47 
illness reports observed in previous studies. These findings also suggest that CHS sensitivity 48 
is highly relevant to host defence. 49 
50 
Key Points 51 
Bovine colostrum supplementation blunts impairment in the sensitivity of in vivo immune 52 
responses following prolonged exercise.  53 
These findings add to previous evidence of bovine colostrum acting as a nutritional 54 
countermeasure to decreased in vitro immunity following prolonged exercise and incidence of 55 
upper respiratory illness in athletes.  56 
1 Introduction 57 
Upper respiratory tract symptoms (URS) are the most common ailment reported by athletes 58 
to medicine clinics at major sporting events [1-3]. It has long been considered that transient 59 
perturbations in host immunity following strenuous training and/or competition increases 60 
susceptibility to infectious (pathogenic) causes of URS [4]. Numerous studies have shown 61 
significant decreases in circulating and mucosal immune function in individuals undergoing 62 
heavy physical exertion [5]. The majority of these studies have relied on in vitro measures of 63 
immune function where the clinical relevance of such investigations is often questioned [6]. 64 
The importance of in vivo measures of immunity to determine the clinical relevance of a 65 
change in immune function in an exercise context has been recognised [7]. The clinical 66 
relevance of such measures is further supported in immune deficient populations (e.g. HIV 67 
positive, children) whereby the degree of responses relate to relevant clinical outcomes 68 
(respiratory infections, mortality) [8-10].  69 
Topical skin exposure to novel antigens (contact sensitisation) such as 70 
Diphenylcyclopropenone (DPCP) allows for the effects of systemic stressors on the induction 71 
and elicitation phases of in vivo T-cell-mediated immune response to be quantified by 72 
oedema and erythema [11-13]. By use of this model of experimental contact sensitisation, 73 
Harper-Smith et al. [14] demonstrated that participation in a single bout of prolonged (2 h) 74 
moderate exercise compared to rest significantly reduced both the induction and the 75 
elicitation of in vivo cell-mediated immunity. Recent work demonstrating that the same 76 
exercise stressor does not impair responses to a skin irritant [15] have further established this 77 
as a controllable, reproducible and valid marker of exercise-induced immunity (antigen T-cell 78 
mediated responses). This rigorous model with control of both the dose and timing of the 79 
sensitisation to the novel antigen permits the investigation of strategies to counter the effects 80 
of prolonged exercise on immunity. 81 
Several nutritional interventions have been proposed as countermeasures to exercise-82 
induced immune dysfunction. Oral supplementation of bovine colostrum (COL) reduces the 83 
episode incidence and days of URS in adults involved in exercise training by a magnitude that 84 
is greater than the smallest clinically important difference [16]. The mechanism(s) behind 85 
such effects remain unclear but it has been proposed that it is linked to COL reducing 86 
perturbations in cellular immunity following prolonged exercise [17]. We have previously 87 
demonstrated that COL blunts the decrease in blood neutrophil effector functions following 88 
prolonged exercise (18,19). Shing et al. [20] observed a prevention of a post-exercise 89 
decrease in cytotoxic/suppressor T cells during an intensive period of training. Although such 90 
in vitro or ex vivo measures are considered sufficiently reliable and sensitive markers of 91 
immunity [7], it is difficult to conclude with any degree of certainty that modulations in these 92 
parameters alone are responsible for the alteration observed in susceptibility to URS. The 93 
cutaneous measures of immunity such as contact hypersensitivity (CHS) represent an 94 
integrated and highly coordinated (in vivo) immune response to a challenge induced by a 95 
novel antigen [21].  96 
To our knowledge, no studies have assessed the effects of COL on the in vivo immune 97 
response to a novel antigen following prolonged exercise. Therefore, the aim of this study 98 
was to investigate the effects of COL supplementation on the induction of a cell-mediated 99 
response to DPCP following prolonged exercise. We hypothesised that COL supplementation 100 
would blunt prolonged exercise-induced decreases in the induction of in vivo immunity. 101 
Although not on the World Anti-Doping Agency’s list of banned substances, supplementation 102 
of COL is not recommended by the governing body because it contains growth factors such 103 
as Insulin-like growth factor I (IGF-I) that “may influence the outcome of anti-doping tests” 104 
[22]. Given that this study may have clinically relevant implications for athletes, the secondary 105 
aim was to investigate whether COL caused any unwarranted changes in IGF-I 106 
concentrations. 107 
2 Materials and methods 108 
2.1 Trial Design 109 
This double-blind randomised placebo controlled trial was approved by the Aberystwyth 110 
University Research Ethics Committee and all experimental procedures were conducted in 111 
line with the Declaration of Helsinki. All participants provided both verbal and written consent 112 
following information on experimental procedures. All laboratory visits involving exercise also 113 
required completion of a physical activity readiness questionnaire (PAR-Q). 114 
2.2 Participants 115 
Thirty four participants were eligible for the present investigation (Figure 1). Participants were 116 
included if they were male, healthy (as determined by PAR-Q), recreationally active, non-117 
smokers and aged 18-45 years. Exclusion criteria were use of regular medication or dietary 118 
supplements, known allergy or intolerances to milk products, eczema or dermatitis on the 119 
upper arm or lower back, regular exposure to ultraviolet radiation, tendency for abnormal 120 
scarring (e.g. keloid), previous contact with DPCP, participation in other research studies that 121 
involved skin patch testing or blood donation or infection four weeks prior to the study. 122 
2.3 Supplementation 123 
Participants were randomly assigned (using a computerised list generated at randomiser.org 124 
by a researcher not involved in data collection) to a COL group (n = 17) or placebo (PLA) 125 
group (n = 17) following stratification on age and aerobic fitness (determined in first 126 
incremental exercise test). COL and PLA powdered supplements were provided in sealed 127 
sachets that did not identify the contents to a study investigator (blinded to group allocation) 128 
for distribution to participants. Participants consumed 20 g a day (10 g morning and evening: 129 
mixed with 250-300 mL of water and consumed on an empty stomach) of COL or an 130 
isoenergetic/isomacronutrient PLA (skimmed milk powder and milk protein concentrate) for 58 131 
days (28 days before and after the main exercise trial, and the 2 days of elicitation) (Figure 2).  132 
2.4 Preliminary visits and standardisation  133 
Participants performed a continuous incremental test (1 kmh-1min-1) following 3 min at 7 134 
kmh-1) to volitional exhaustion on a treadmill with a 1% grade (PPS 55med, Woodway 135 
GmbH, Weil am Rhein, Germany). Expired gas was analysed by an online breath-by-breath 136 
gas analysis system (Jaeger Oxycon Pro, Hoechberg, Germany). Strong verbal 137 
encouragement was provided in the later stages of the test to encourage maximal effort. 138 
Maximal oxygen uptake ( max) was determined as the highest 30 s average during the 139 
test.  140 
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At least 48 h following the incremental test and after an overnight fast (from midnight), 141 
participants reported to the laboratory at 10:30 for a blood sample (Baseline, day 0) prior to 142 
commencing supplementation. Fourteen days into the supplementation period, max of 143 
participants was re-tested. Seven days later, participants performed a familiarisation trial 144 
consisting of a 1 h run to habituate with study procedures and verify speed equivalent to 60% 145 
max. 146 
For the 24 h prior to the main experimental trial, participants were provided a standardised 147 
diet of 60% (energy from) carbohydrate: ~5.4 gkg-1 body mass (BM); 25% fat: ~1.0 gkg-1 BM; 148 
15% protein: ~1.3 gkg-1 BM and water: 35 mLkg-1 BM [23]. This diet matched the estimated 149 
daily energy expenditure requirements for each participant estimated by the equation of 150 
Harris and Benedict [24] multiplied by a physical activity factor of 1.5 (note: relative rest was 151 
required on this day). This diet did not include any caffeine or alcohol and participants were 152 
also asked to avoid any exercise during this period. On the day of the main trial, participants 153 
were provided a standardised breakfast at 07:30 (total energy: 7.5 kcalkg-1 BM, 154 
carbohydrate: ~1 gkg-1 BM [60%], fat: ~ 0.2 gkg-1 BM [25%] and protein: ~0.2 gkg-1 BM 155 
[15%]). They remained in the lab for 3 h (during which a bolus of water equivalent to 5 mLkg-1 156 
BM was provided). To further standardise dietary intake, participants were provided with a 157 
lunch prior to departure on the day of the main exercise trial (total energy: 5 kcalkg-1 BM, 158 
carbohydrate: ~ 0.6 gkg-1 BM [50%], fat: ~ 0.2 gkg-1 BM [34%] and protein: ~0.2 gkg-1 BM 159 
[16%]). 160 
2.5 Experimental procedures 161 
2.5.1 Main exercise trial 162 
A resting blood sample (Pre-exercise) was collected at 10:45 (after 10 min seated rest) before 163 
the 2 h run at 60% max commenced at 11:00. All participants were permitted diluted 164 
cordial (four volumes of water to 1 volume of sugar-free cordial at 2 mL per kg of BM) every 165 
15 min during the exercise but not at end of the exercise. Expired gas (2 min) was analysed 166 
with measurements commencing at 30, 60 and 90 min of exercise (Jaeger Oxycon Pro, 167 
Hoechberg, Germany). Heart rate (Polar S610, Polar Electro Oy, Kempele, Finland) and 168 
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rating of perceived exertion (RPE: Borg scale [25]) were monitored and recorded every 15 169 
min during the protocol. A venous blood sample was collected immediately post-exercise 170 
(Post-exercise). Participants showered (without the use of body washes or shower gels) and 171 
returned to the laboratory within 20 min of exercise completion. 172 
2.5.2 Induction of contact sensitivity 173 
Participants were sensitised at 13:20 using a single patch (22.8 µL of 0.125% DPCP in 174 
acetone, 30 µg·cm-2 DPCP) applied to the mid-lower back in accordance with previous 175 
studies [14,15,21]. Following application, the patch remained in place for exactly 48 h. 176 
Participants were instructed to avoid alcohol and exercise during this period.  177 
2.5.3 Elicitation of immune memory 178 
Exactly 28 days following the induction of immune-specific memory (sensitisation), and in 179 
accordance with previous studies [14,15, 21] participants reported to the laboratory for a 180 
series of DPCP patches (10 µL of 0.0048%, 1.24 µg·cm-2; 0.0076%, 1.98 µg·cm-2; 0.0122%, 181 
3.172 µg·cm-2; 0.01953%, 5.08 µg·cm-2; 0.03125%, 8.12 µg·cm-2; and 0%, 100% acetone) to 182 
be applied to the volar aspect of their right upper arm, at the same time (13:20). To minimise 183 
anatomical variability these patches were applied in a randomly allocated order (matched 184 
between groups). All patches were removed after exactly 6 h.  185 
2.5.4 Assessment of cutaneous responses 186 
Participants returned to the laboratory 24 and 48 h following the application of patches for 187 
cutaneous responses (oedema, by skinfold thickness) to be measured, in triplicate, using 188 
modified skin fold callipers (Baty, West Sussex, UK) in accordance with previous studies 189 
[14,15, 21]. During this 48 h period, and the 24 h prior to application of the patches, 190 
participants were requested to avoid any exercise and alcohol. The dose-response curves 191 
were used to conduct sensitivity analyses to determine the minimum DPCP dose required to 192 
elicit a (positive) response. Summed increases in skinfold thickness were determined by 193 
adding values for all doses.  194 
2.6 Blood sampling  195 
Participants remained seated, performing minimal movement for 10 min prior to each blood 196 
sample with the exception of immediately post-exercise, which were drawn within a few min 197 
of exercise cessation. Blood samples were collected by venepuncture (21 gauge precision 198 
needle [Becton-Dickinson, Oxford, UK]) from an antecubital vein into a vacutainer (Becton-199 
Dickinson, Oxford, UK) containing tripotassium ethylene diamine tetraacetic acid (K3EDTA). A 200 
small aliquot was taken from the K3EDTA tube for whole blood measures, whilst the 201 
remaining sample was centrifuged at 1500 g for 10 min at 4°C. Ailquots of plasma were 202 
stored at -80°C for later analysis. 203 
2.7 Blood analysis 204 
Leukocyte counts (ABX Pentra 60 C+, Horiba Medical, Montpellier, France) were determined 205 
on K3EDTA treated whole blood. Glucose and lactate were determined on EDTA plasma 206 
(Biosen C-Line, EKF Diagnostic, London, UK). IGF-I concentration was quantified in duplicate 207 
pre-treated (to release IGF-I from binding proteins) plasma samples at baseline and pre-208 
exercise (4 weeks following supplementation) via a commercially available enzyme-linked 209 
immunosorbent assay (R&D Systems, Abingdon, UK). 210 
2.8 Statistical analysis 211 
Sample size estimation: It was not possible to use previous data to perform power 212 
calculations since there are no other studies that have used the present methods to assess in 213 
vivo immune function with this supplement. However, we have undertaken a number of 214 
studies on various immune markers and, on average, have observed a large effect (Cohen's 215 
d = 1.25) with the dosage of bovine colostrum used in the present study (e.g. 18,19,26). In 216 
order to detect such a magnitude of effect in this study a sample size of n = 15 per group (n = 217 
30 in total) is required to provide >90% power. 218 
Data shown in the text, tables and figures are presented as mean ± standard deviation unless 219 
stated otherwise. Statistical analysis of the dose-response curves was performed using 220 
Graph Pad Prism version 7 (GraphPad, San Diego, USA).  Statistical analyses of all blood 221 
measures were performed via SPSS (v22.00; SPSS Inc., Chicago, IL, USA). If possible, data 222 
not normally distributed were normalised with log or square root transformation before further 223 
analysis, otherwise non-parametric tests were used. A two factor mixed ANOVA (group × 224 
time) was carried out on blood leukocytes, plasma glucose, lactate and IGF-I. Any significant 225 
main effects in the ANOVA were further analysed by post hoc 2 tailed paired or independent 226 
t-tests with Holm-Bonferoni correction. Independent t-tests were used to compare HR, oxygen 227 
uptake (% max, ), RPE, and summed skinfold thickness (at 48 h). Mann Whitney U 228 
test was used to assess summed skinfold thickness responses to DPCP at 24 h. Statistical 229 
significance was accepted at p < 0.05. 230 
3 Results 231 
3.1 Participants 232 
From initially screened and included volunteers, 31 participants were analysed in this trial 233 
(Figure 1). Follow up was not possible in 2 participants from COL group due to injury (outside 234 
of experimental protocol which also required acute anti-inflammatory treatment) and overseas 235 
travel leading to prolonged period where supplement was not consumed. One participant 236 
from PLA group was excluded following a change in circumstances (prescribed medication) 237 
meaning they no longer met the eligibility criteria. Groups remained well matched with no 238 
significant differences in physical characteristics (Table 1). 239 
3.2 Physiological responses to exercise 240 
There was no significant difference in absolute (p = 0.979) or relative (p = 0.423) trial  241 
between the COL (2646 ± 254 ml·min-1; 61.4 ± 2.3%  max) and PLA groups (2649 ± 329 242 
ml·min-1; 62.3 ± 3.3% max). Similar mean HR (COL, 150 ± 14 bpm; PLA, 150 ± 11 bpm; 243 
p = 0.910) and RPE (COL, 13.0 ± 1.0; PLA, 12.6 ± 1.2; p = 0.365) values were observed 244 
during the main exercise trials. There was no significant time (p = 0.502), group (p = 0.319) or 245 
interaction effect (p = 0.633) for plasma glucose (COL, pre-exercise: 4.5 ± 0.4 mmol·L-1, post-246 
exercise: 4.7 ± 0.7; PLA, pre-exercise: 4.4 ± 0.6, post-exercise: 4.4 ± 0.6). There was a 247 
significant time effect for plasma lactate (p < 0.001) with a significant increase from pre-248 
2OV! 2OV!
2OV!
2OV!
2OV!
exercise (p < 0.001) to post-exercise but there was no group (p = 0.804) or interaction effect 249 
(p = 0.506 (COL, pre-exercise: 1.4 ± 0.4 mmol·L-1, post-exercise: 1.9 ± 0.5; PLA, pre-250 
exercise: 1.3 ± 0.2, post-exercise: 2.0 ± 0.7).  251 
3.3 Immune cell counts 252 
No significant group or interaction effects were evident for total or differential leukocyte counts 253 
(Table 2). A main effect of time was observed for all leukocytes (Table 2).  254 
3.4 Plasma IGF-I 255 
There was a significant time effect for plasma IGF-I (p = 0.003) but there was no group (p = 256 
0.649) or interaction effect (p = 0.987) (COL, baseline: 125 ± 23 ng·mL-1, pre-exercise (4 257 
weeks): 135 ± 31 ng·mL-1; PLA, baseline: 131 ± 33 ng·mL-1, pre-exercise: 140 ± 33 ng·mL-1). 258 
3.5 In vivo immune responses 259 
The summed skinfold response was not significantly different between groups at 24 h (COL: 260 
1.84 ± 1.79 mm, PLA: 1.01 ± 0.92 mm, p = 0.124) or 48 h (COL, 3.61 ± 3.21 mm; PLA, 2.83 ± 261 
1.64 mm, p = 0.405) (Figure 3). Analysis of the dose-response curves allowed determination 262 
of the minimum DPCP dose required to elicit a positive response (i.e. sensitivity) (Figure 4). 263 
The minimum dose required at 24 h was 0.4 µg·cm-2 and 0.8 µg·cm-2 for COL and PLA 264 
groups respectively (p < 0.001), indicating a dose 2.0 fold greater was required to elicit a 265 
positive response in the PLA group. At 48 h, the threshold was 0.4 µg·cm-2 and 0.7 µg·cm-2 266 
for COL and PLA groups respectively (p = 0.023), indicating a dose 1.8 fold greater was 267 
required to elicit a positive response in the PLA group. Direct comparisons between groups at 268 
each dose revealed a greater skinfold thickness response in COL compared to PLA for the 269 
lowest DPCP dose at both 24 h (COL: 0.22 ± 0.25 mm, PLA: 0.06 ± 0.11 mm, p = 0.011) and 270 
48 h (COL: 0.42 ± 0.50 mm, PLA: 0.16 ± 0.19 mm, p = 0.048).    271 
4 Discussion 272 
The aim of this study was to investigate the effects of COL supplementation on the induction 273 
of in vivo immune responses to a novel antigen following prolonged exercise. Previous 274 
evidence suggests that completion of prolonged exercise prior to sensitisation to the novel 275 
sensitising chemical, DPCP, can impair the induction of antigen-specific memory [14]. This 276 
provides a robust method to evaluate the effects of purported nutritional countermeasures on 277 
exercise-induced immune dysfunction in vivo. COL did not significantly affect the overall 278 
summed skinfold response to DPCP but COL supplementation induced greater sensitivity of 279 
antigen-specific memory recalled 4 weeks following initial sensitisation. A greater contact 280 
hypersensitivity response to the lowest DPCP dose was also evident in the COL group but 281 
there was no difference at the higher doses. 282 
The findings of the present study extend our current knowledge on the benefits of COL as an 283 
immune-enhancing supplement in humans. Evidence to date suggests that the effects of COL 284 
may be more apparent in the early recovery period following prolonged exercise [18,19]. 285 
However, the immunoprotective effects of COL (within a model of exercise-induced immune 286 
dysfunction) thus far in humans have only been demonstrated with in vitro measures of blood 287 
neutrophil function. Although investigations on whole blood maintains the proximity of 288 
leukocytes and the extracellular milieu of leukocytes compared to other in vitro measures of 289 
immune function, the use of in vivo measures is considered more clinically relevant [7, 11, 290 
22]. We previously demonstrated that COL limits the increased salivary bacterial load in 291 
physically active males during the winter months [26], and proposed this to be a relevant 292 
marker of in vivo (innate) immunity that needed further testing in an exercise immunology 293 
context. Here, we have used a controllable, reproducible and valid marker of exercise-294 
induced immunity in vivo.  295 
With regard to the overall reactivity to DPCP, we did not observe any significant effects of 296 
COL. In the one previous study investigating a nutritional countermeasure (carbohydrate 297 
supplementation during exercise) using this experimental model [21], there were no 298 
significant effects on either sensitivity or overall reactivity to DPCP following prolonged 299 
exercise. Previous studies [14, 15] have consistently shown that participation in prolonged 300 
exercise prior to primary sensitisation to DPCP, decreases summed responses of all 301 
challenge sites and increases the minimum dose (threshold) required to elicit a positive 302 
response during recall of immune specific memory. As a result of exercise-induced 303 
impairment in cell-mediated immunity, a three-four fold greater (i.e. lower sensitivity) DPCP 304 
dose was required to evoke a positive response in the exercise group than the non-exercising 305 
control group. Similarly, when compared to the resting groups of Harper-Smith et al [14] and 306 
Diment et al. [15], the exercise groups in this study demonstrate a reduction in summed 307 
responses (Figure 3). However, the findings of this study demonstrate that COL acts as a 308 
nutritional countermeasure to prolonged exercise-induced decrements in the sensitivity of 309 
clinically relevant in vivo immune responsiveness to a novel antigen.  310 
There is unequivocal evidence that a threshold effect exists for cutaneous sensitisation [27, 311 
28, 29]. Indeed, with experimental contact dermatitis, there are threshold doses where an 312 
allergic state is not clinically elicited despite prior sensitisation [30]. In contrast, a major goal 313 
of vaccines is to sensitise host defences for future exposure to a pathogen [31]. Hence, 314 
greater immune responses by the host during exposure to low doses of such antigens are 315 
deemed to be beneficial for limiting the spread of the infectious agent. Previous findings of no 316 
inhibitory effect of prolonged exercise on skinfold responses to the irritant, croton oil, provide 317 
evidence that in the context of DPCP, responses are dependent on cell-mediated events 318 
rather than local inflammatory processes [15]. Given that a recent meta-analysis [16] of five 319 
randomised controlled trials (including one from our laboratory) of COL supplementation 320 
showed a reduction in the incidence of URS during exercise training [26, 32-34], it is likely 321 
that an increase in recall sensitivity provides a mechanistic explanation for reduced URS. It 322 
will be useful, however, for future studies to monitor URS in the period following DPCP 323 
sensitisation. It is beyond the scope of the findings of this study and previous evidence to 324 
suggest that T-cell mediated responses at lower doses of DPCP are of greater biological 325 
significance (i.e. risk of URS) than summed responses. Our data, however, does at least 326 
suggest that the sensitivity of cutaneous recall responses to DPCP give a better indication of 327 
clinically relevant immunological changes following nutritional (bovine colostrum) 328 
interventions.  329 
It must be acknowledged that the present study design does not allow us to fully establish 330 
whether the potential effect of COL on the immune system occurred during the induction 331 
and/or the elicitation of cell-mediated immune responses. Limiting consumption of COL to the 332 
4 weeks between induction and elicitation only might have provided mechanistic insight 333 
regarding this question, but this does not reflect the application of COL in the real world 334 
setting. Within the field of contact sensitisation, the main factor considered to determine the 335 
extent of elicitation is the strength of the induction [30]. In addition, the stronger the degree of 336 
induction, the lower the dose that sensitised individuals will react to upon any recall challenge 337 
[12]. Further, the evidence that the induction phase of T cell memory is more susceptible to 338 
the effects of prolonged exercise than the elicitation phase [14] may also point towards the 339 
period where participants would have benefited most from a nutritional countermeasure such 340 
as COL. Biswas et al. [35] did demonstrate that COL can differentially affect in vitro 341 
stimulation of human peripheral blood mononuclear cells by enhancing IFNγ production 342 
during weak antigenic stimulation but not under conditions of strong antigen stimulation.  343 
Although T cell infiltration plays a central role in the orchestration of CHS responses, this is 344 
initiated by the non-specific ‘sensitivity’ of other local (dendritic, Langherhans) cells that 345 
respond to perturbations induced by the antigen [36]. In addition to the induction phase, 346 
recent evidence suggests that the recruitment of antigen-primed CD8+T cells in response to 347 
elicitation of immune memory may also depend on infiltration and chemoattractants released 348 
by inflammatory cells (e.g. neutrophils) [37, 38]. It was a limitation of the present study that 349 
we did not measure circulating cytokines or in vitro measures of immunity alongside in vivo 350 
immunity. These may have provided some insight into the mechanisms of action or the 351 
effects of COL on signals that may have triggered the migration and maturation of cells 352 
involved in the in vivo response and whether possible tissue priming effects resulted in 353 
enhanced immunosurveillance and explain the greater responses at lower concentrations of 354 
DPCP in the COL group. Future studies should also explore the effects of COL 355 
supplementation on immune parameters prior to both induction and elicitation separately in 356 
order to further determine mechanisms. However, it is important to note that the primary 357 
outcome measure, CHS, represents the whole integrated in vivo immune response that is 358 
considered the most clinically relevant measure [7, 11, 22] and also that in vitro responses do 359 
not necessarily predict in vivo responses [15, 21]. CHS measurements recorded prior to the 360 
24 h time point may also provide useful information on the improved sensitivity in future 361 
studies. If there were any modulatory effects of COL on performance or stress responses, this 362 
could also contribute indirectly to effects on the immune responses. However, the present 363 
findings of similar leukocyte trafficking, and physiological measures, between groups (along 364 
with similar findings in previous studies that also found no difference in stress hormone 365 
responses, e.g. 18, 19) suggest that subjects in this study were exposed to a matched 366 
exercise-induced stress, supporting previous evidence that the effects of COL are not due to 367 
such indirect mechanisms.  368 
This study provides further evidence that COL, as a supplementation regimen that induces 369 
clinically relevant benefits to immune health, does not increase circulating concentrations of 370 
IGF-I compared to an isoenergetic/isomacronutrient placebo.  Previous evidence from one 371 
laboratory had suggested increases in IGF-I following short-periods (≤ 2 weeks) of COL 372 
supplementation [39,40] but one of these studies was unable to confirm that it was orally 373 
administered IGF-I that appeared in the circulation (i.e. IGF-I was not absorbed from COL). 374 
An important limitation in these studies was the choice of placebo (dextrose only) as the 375 
addition of daily protein supplementation has been shown to induce similar elevations in IGF-I 376 
[41]. Subsequently, changes in circulating IGF-I following COL have not been replicated by 377 
other investigators including larger doses and longer duration of supplementation [42-45], 378 
which in one study was supported by no positive values in urine samples analyzed within an 379 
International Olympic Committee-accredited laboratory [45]. Furthermore, in a previous study 380 
(26) we conducted a comprehensive metabolomics analysis and found no differences that 381 
would suggest COL could influence the outcome of a doping test. The balance of evidence, 382 
therefore, does not seem to support the claim that COL can increase IGF-I or influence 383 
doping tests.  384 
5 Conclusion 385 
In summary, COL did not significantly effect the overall reactivity of in vivo response to a 386 
novel antigen but did blunt the prolonged exercise-induced decrease in sensitivity of the 387 
immune responsiveness. A difference in response to DPCP was evident at the lowest recall 388 
dose but not at the higher doses. Together with previous findings (e.g. effects of COL on host 389 
defence and illness susceptibility) these results may also suggest that the sensitivity of CHS 390 
responses are highly relevant to host defence and in vivo protection against infection. The 391 
present study was undertaken in a fed state (to replicate real-world practices of athletes) with 392 
a recreational athlete population, and presents the first evidence of a nutritional strategy to 393 
counter exercise-induced immunodepression assessed via an established, clinically relevant 394 
in vivo marker of immunity.   395 
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Table 1. Participant characteristics. 523 
 COL PLA p value 
Age (years) 23.4 ± 4.7 25.3 ± 5.5 0.307 
Body mass (kg) 76.4 ± 9.2 73.7 ± 8.1 0.388 
Height (m) 1.81 ± 0.05 1.79 ± 0.07 0.352 
max (ml·min-1) 4272 ± 410 4152 ± 529 0.489 
max (ml·kg-1·min-1) 56.6 ± 8.0 56.4 ± 5.3 0.962 
  524 
2OV!
2OV!
Table 2. Immune cell counts prior to and following prolonged running.  525 
*Significant main effect of time (p < 0.001). Post hoc (analysis for time effects):  †Significant 526 
difference compared to Baseline (p < 0.05), ‡Significant difference compared to Pre-exercise. 527 
  528 
 
 
 
Cell count, 109·L-1 
 
 
 
Baseline 
 
 
 
Pre-exercise 
 
 
 
Post-exercise 
p values 
group 
time 
interaction 
Total leukocytes    †‡ 0.601 
COL 5.5 ± 1.8 5.7 ± 1.3 11.6 ± 4.3 < 0.001* 
PLA 4.8 ± 1.2 5.3 ± 0.9 12.0 ± 5.7 0.399 
Neutrophils   † †‡ 0.566 
COL 3.0 ± 1.7 3.2 ± 1.2 8.5 ± 4.5 < 0.001* 
PLA 2.3 ± 0.8 2.9 ± 0.7 8.5 ± 5.2 0.382 
Monocytes    †‡ 0.467 
COL 0.5 ± 0.2 0.5 ± 0.1 0.9 ± 0.4 < 0.001* 
PLA 0.5 ± 0.1 0.5 ± 0.1 0.9 ± 0.4 0.337 
Total lymphocytes    †‡ 0.459 
COL 1.7 ± 0.4 1.6 ± 0.4 2.2 ± 0.6 0.001* 
PLA 1.8 ± 0.5 1.7 ± 0.4 2.4 ± 0.6 0.939 
Neutrophil:lymphocyte   † †‡ 0.371 
COL 1.9 ± 1.7 2.1 ± 1.0 3.9 ± 1.7 < 0.001* 
PLA 1.3 ± 0.4 1.8 ± 0.5 3.6 ± 2.0 0.430 
Figure 1. Schematic diagram of study design. 529 
Figure 2. Flow chart of study participants. 530 
Figure 3. Summed increase in skinfold thickness at 24 h and 48 h in response to DPCP 531 
challenge 28 days after sensitisation *Participants of the non-exercising control arms (n = 32) 532 
from previous studies [14,15] serve as an additional comparison (i.e. 120 min of seated rest 533 
prior to sensitisation with DPCP) to demonstrate typical decreases in summed skinfold 534 
responses to DPCP with prolonged exercise. Columns indicate mean values for each group. 535 
Error bars represent 95% confidence intervals. 536 
Figure 4. Skinfold responses to the full dose-series DPCP challenge 28 days after 537 
sensitisation. *Participants of the non-exercising control arms (n = 32) from previous studies 538 
[14,15] serve as an additional comparison (i.e. 120 min of seated rest prior to sensitisation 539 
with DPCP) to demonstrate typical decreases in sensitivity of immune-specific memory to 540 
DPCP with prolonged exercise. Points indicate mean values for each group. Error bars 541 
represent 95% confidence intervals. †Significant difference between PLA and COL (p < 0.05). 542 
